BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics(BCLI)

NEW YORK, NY
Biotechnology

Focus: Autologous, adult stem cell therapy technology

BrainStorm Cell Therapeutics is a life sciences company focused on Autologous, adult stem cell therapy technology.

Cell TherapyGene Therapy
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT04681118Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
N/A
MSC-NTF cells transplantation
Amyotrophic Lateral Sclerosis
Phase 1/2
Clinical Trials (1)
NCT01051882Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
Phase 1/2
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Amyotrophic Lateral Sclerosis
Phase 2
Clinical Trials (1)
NCT01777646Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Phase 2
Clinical Trials (1)
NCT02017912Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
Phase 2
Clinical Trials (1)
NCT03799718Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS
Phase 2
Phase 3
Clinical Trials (1)
NCT06973629Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Phase 3
Clinical Trials (1)
NCT03280056Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 7 clinical trials
SEC Filings: 2 available

Financials (FY2024)

R&D Spend
$11M23%
Net Income
-$17M
Cash
$1M